Sigma Genetics Inc.

Intracellular delivery is the bottleneck to life saving cell and gene therapies. Current delivery methods are inefficient, unsafe, expensive, and don’t scale, constraining both in vivo genetic medicines and ex vivo cell manufacturing.

• Previously raised $4M from world class venture capital firms, hedge funds, angel investors, and non dilutive grants including the Andy Hill CARE Fund and U.S. Department of Defense.
• Overview:
• In vivo PLV validation: PLVs deliver CAR‑T pDNA constructs to T cells in vivo; CD19 CAR‑T candidates drove significant B‑cell depletion in mice (Spleen and PBMC B cells to 0-10% by day 28).
• Safety + biodistribution: Systemic PLV pDNA delivery shows strong tolerability and biodistribution beyond the liver, including in non‑human primates.
• Ex vivo performance: Magnetoporation delivers >22× more live cells and >16× more transfected primary human T cells vs. electroporation and supports pDNA payloads up to 10kb.
• Cell line platform POC: high yield transfection in human trophoblast stem cells (hTSCs) with minimal cell loss, supporting next‑gen producer cell line development.
• Series A: Targeting $10M Series A to fund IND enabling studies for two CAR‑T programs, develop hTSC producer lines, and deployment of Magnetoporator platform for research and clinical use of cell therapies.